Carrier effects on biological activity of amphotericin B.

Brajtburg, J; Bolard, Jacques

doi:10.1128/cmr.9.4.512-531.1996

Cited by 31 publications

(42 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…AmB is characterized by molecular aggregation in aqueous medium at certain concentrations, which is related to its activity [13][14][15] and toxicity [15][16][17][18]. According to pharmaceutical literature, three forms of the drug are identified in aqueous solution: monomers at 0.2 mg/mL, water-soluble aggregates (e.g., of oligomers) at above 1 mM and water insoluble aggregates at a concentration above 10 mM [19][20][21]. Oligomers display an absorption maximum between 328 and 340 nm whilst aggregates show wide absorption [22].…”

Section: Resultsmentioning

confidence: 99%

Amphotericin B microparticles ‘AmbiShell’ from phospholipid and gelatin: Development and investigation by combined DLS and SANS resolves the core‐shell structure

Johnson

Nawroth

Khoshakhlagh

et al. 2014

Euro J Lipid Sci & Tech

View full text Add to dashboard Cite

A novel homogenous core‐shell formulation ‘AmbiShell’ of the hydrophobic antifungal polyene drug Amphotericin B was prepared from the pure drug, lecithin, and gelatin. The established ‘Hydrophilic Solubilisation Technology’ (HST) was used for embedding the lipophilic drug with lecithin and gelatin, yielding core‐shell microparticles of 1 µm size. The particle size of the drug, the formulation, and the thickness of the coating were investigated by using dynamic light scattering (DLS), microscopy, UV–Visible spectroscopy and small angle neutron scattering (SANS). The drug in the formulation was not in the oligomer form but in a competent uptake form, as shown by the UV–Visible spectroscopy. The DLS and microscopy depicted the product to consist of spheres (∼1 µm). The SANS experiment using deuterium contrast matching of the drug cores revealed a thin layer span of 5.6 nm, which is similar, but slightly larger as compared to the biological lipid membranes. The finding offers opportunities for further improvements of the formulation, e.g., by surface modification. A soluble core‐shell formulation ‘AmbiShell’ of the hydrophobic antifungal polyene drug Amphotericin B was generated from drug, lecithin, and gelatin. The span of the lipid–gelatin shell was estimated by neutron scattering SANS with deuterium contrast matching of the drug core.

show abstract

Section: Resultsmentioning

confidence: 99%

Amphotericin B microparticles ‘AmbiShell’ from phospholipid and gelatin: Development and investigation by combined DLS and SANS resolves the core‐shell structure

Johnson

Nawroth

Khoshakhlagh

et al. 2014

Euro J Lipid Sci & Tech

View full text Add to dashboard Cite

show abstract

“…The mechanism of action, which is shared in common with other polyenes, is based on the binding of the hydrophobic moiety of the amphotericin B suspension to the spherule's cell membrane ergosterol moiety. 6 This binding produces damage to the cell membrane and, potentially, cell death. Amphotericin B also has the capability of binding to the cholesterol of mammalian cell membranes, which is responsible for a major fraction of its toxic potential.…”

Section: Chemistry and Mechanism Of Actionmentioning

confidence: 99%

Amphotericin B and Coccidioidomycosis

Johnson

Einstein

2007

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

Prior to the 1950s no effective therapy for coccidioidomycosis existed. The advent of amphotericin B ushered in the therapeutic era for coccidioidomycosis. Until this time amphotericin B and its lipid congeners have been regarded as the "gold standard" of therapy for severe pulmonary and disseminated coccidioidomycosis. The availability of azoles and later triazoles for the past three decades have relegated the amphotericins into a rescue mode, used mainly in widely disseminated cases, azole intolerance, or when there are contraindications to Azoles, such as pregnancy. In meningitis the intrathecal use of amphotericin B is still used frequently by some clinicians alone or with a triazole. The newer lipid preparations, while more expensive, have significantly reduced toxicity, particularly nephropathy.

show abstract

“…Amphotericin B (Amp B) has acquired the ''gold'' standard status for treatment of various fungal diseases including aspergillosis [7]. Several strategies have been suggested to improve the therapeutic effectiveness of Amp B.…”

Section: Introductionmentioning

confidence: 99%

“…Several strategies have been suggested to improve the therapeutic effectiveness of Amp B. The most promising approach has involved the modification of the physical state of Amp B by developing various Amp B lipid formulations [7]. Some of the lipid formulations of Amp B are now commercially available, i.e., Abelcet, Amphocil, Ambisome, etc.…”

Section: Introductionmentioning

confidence: 99%

Tuftsin-mediated immunoprophylaxis against an isolate ofAspergillus fumigatusshows less in vivo susceptibility to amphotericin B

Khan

Ahmad

Moin

et al. 2005

FEMS Immunology &Amp; Medical Microbiology

View full text Add to dashboard Cite

In the present study, we evaluated the immunopotentiating efficacy of tuftsin against experimental murine aspergillosis in both normal and immunodebilitant BALB/c mice. The animals were challenged with an isolate of Aspergillus fumigatus (1x10(8) cfu/mouse) that was showing less susceptibility to lower doses of amphotericin B in murine animal model. Co-administration of the immunomodulator tuftsin and liposomised-amphotericin B was found to be highly effective in the treatment of systemic infection of A. fumigatus in both immunocompetent and leukopenic mice. Moreover, pre-treatment of mice with liposomised-tuftsin prior to challenging them with A. fumigatus infection and subsequent treatment with tuftsin-bearing liposomised-amphotericin B was found to be extremely efficient in successful elimination of fungal pathogen. In another set of experiments, tuftsin-mediated antigen-specific memory antibody response was also assessed by immunizing the animals with A. fumigatus cytosolic antigen. The animals that received a booster 150 days after the first immunization with tuftsin-liposomes-antigen showed more resistance to A. fumigatus infection in comparison with the naïve animals.

show abstract

Carrier effects on biological activity of amphotericin B.

Cited by 31 publications

References 83 publications

Amphotericin B microparticles ‘AmbiShell’ from phospholipid and gelatin: Development and investigation by combined DLS and SANS resolves the core‐shell structure

Amphotericin B microparticles ‘AmbiShell’ from phospholipid and gelatin: Development and investigation by combined DLS and SANS resolves the core‐shell structure

Amphotericin B and Coccidioidomycosis

Tuftsin-mediated immunoprophylaxis against an isolate ofAspergillus fumigatusshows less in vivo susceptibility to amphotericin B

Contact Info

Product

Resources

About